other
confidence high
sentiment neutral
materiality 0.10
Design Therapeutics shareholders re-elect three directors, ratify EY as auditor
Design Therapeutics, Inc.
- Three Class II directors re-elected: Simeon George (47.5M for), Arsani William (49.0M), Deepa Prasad (49.0M); broker non-votes ~3.35M.
- Ratification of Ernst & Young as independent auditor for FY2023 approved: 52.5M for, 437 against, 123,262 abstentions.
- Annual meeting held May 31, 2023; 55,945,551 shares outstanding as of record date April 3, 2023.